Ascendis Pharma A/S Stock News

COPENHAGEN, Denmark, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidate

Ascendis has a PDUFA date of June 25, 2021 for its lead indication. However, what makes this pre-market stage company so valuable is its TransCon platform.

– Event will provide an overview of how A s cendis is applying its TransCon ™ technology platform and its unique algorithm for product innovation to the therapeutic area of o ncology –

Shares of Ascendis Pharma (NASDAQ:ASND) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 365.52% over the past year to ($2.70), w

– European Medicines Agency (EMA) validated the Marketing Authorisation Application (MAA)  f or TransCon TM hGH (lonapegsomatropin) in pediatric growth hormone deficiency (GHD) –

COPENHAGEN, Denmark, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical ne

COPENHAGEN, Denmark, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical ne

Chr. Hansen Holding A/S (OTCMKTS:CHYHY) was upgraded by research analysts at Goldman Sachs Group from a “sell” rating to a “neutral” rating in a report issued on Tuesday, The Fly reports. A nu

Chr. Hansen Holding A/S (OTCMKTS:CHYHY) has been assigned a consensus rating of “Hold” from the eight ratings firms that are covering the stock, Marketbeat reports. Three equities research analyst

Denmark stocks higher at close of trade; OMX Copenhagen 20 up 0.65%

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned a consensus rating of “Buy” from the fourteen research firms that are presently covering the company, Marketbeat.com reports. One analyst ha

Nuveen Asset Management LLC lowered its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 31.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The

Wall Street brokerages expect Ascendis Pharma A/S (NASDAQ:ASND) to post sales of $1.94 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for

Credit Suisse Group reaffirmed their neutral rating on shares of Chr. Hansen Holding A/S (OTCMKTS:CHYHY) in a report issued on Tuesday, The Fly reports. Several other research analysts have also issue

JBS S A/S (OTCMKTS:JBSAY) and Cal-Maine Foods (NASDAQ:CALM) are both consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their